Company
Cepheid
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
45
510(k), De Novo and PMA
Device trials
3
As lead sponsor, any status
Adverse event reports
16
Received Nov 1, 2025 to Nov 20, 2026
Recall records
19
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$0
1 Form D offering, 2012 to 2012
Equity
$0
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $5.2M raised of $5.2M sought, first sale Dec 20, 2012, 2 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Dec 20, 2012 | Equity Issued in a merger or acquisition; not counted as money raised | $5.2M | $5.2M | 2 | Rule 506 | Form D ↗Jan 28, 2013 |
Company details
From the company's latest Form D.
- Legal name
- CEPHEID
- Headquarters
- Sunnyvale, California
- Incorporated
- California over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1037760 ↗
Executives, directors and promoters
As listed on the latest Form D.
13 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 45 since 2015.
K262971 · Decided Oct 30, 2026 · 65 days after receipt
Device type: Multiplex Nucleic Acid Detection System For Biothreat Agents (QVR) · Laboratory Medicine & Pathology
K263333 · Decided Oct 22, 2026 · 30 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
K263120 · Decided Oct 2, 2026 · 28 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
42 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT03125460 · 424 participants · Start Dec 2016 · Primary completion Feb 2019
Device: Xpert Bladder Cancer Monitor · For: Bladder Cancer
Sites: Palo Alto, California; Denver, Colorado; Englewood, Colorado · 17 sites in all
- Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)Completed
NCT03421626 · 266 participants · Start Nov 8, 2017 · Primary completion Aug 20, 2018
Device: Xpert BCR-ABL Ultra · For: Leukemia, Myelogenous, Chronic
Sites: Fort Lauderdale, Florida; Boise, Idaho; Columbia, South Carolina · 7 sites in all
NCT02461576 · 966 participants · Start Jul 2015 · Primary completion Feb 24, 2017
Device: Xpert HIV-1 VL Assay · For: Human Immunodeficiency Virus
Reports received
16
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
16
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 7 | 0 | 0 | 0 |
| Jan 24 | 7 | 0 | 0 | 0 |
| Feb 24 | 3 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 1 | 1 | 0 | 0 |
| May 24 | 0 | 0 | 1 | 0 |
| Jun 24 | 2 | 0 | 0 | 0 |
| Jul 24 | 0 | 2 | 0 | 0 |
| Aug 24 | 0 | 2 | 0 | 0 |
| Sep 24 | 0 | 1 | 0 | 0 |
| Oct 24 | 1 | 0 | 0 | 0 |
| Nov 24 | 4 | 1 | 0 | 0 |
| Dec 24 | 4 | 0 | 0 | 0 |
| Jan 25 | 3 | 0 | 0 | 0 |
| Feb 25 | 6 | 0 | 0 | 0 |
| Mar 25 | 5 | 0 | 1 | 0 |
| Apr 25 | 4 | 0 | 0 | 0 |
| May 25 | 2 | 0 | 0 | 0 |
| Jun 25 | 2 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 2 | 0 | 0 | 0 |
| Sep 25 | 5 | 0 | 0 | 0 |
| Oct 25 | 6 | 0 | 0 | 0 |
| Nov 25 | 4 | 0 | 0 | 0 |
| Dec 25 | 3 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 2 | 0 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 1 | 0 | 0 | 0 |
| Jun 26 | 2 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 2 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
2 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
4 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Xpert MTB/RIF. Model Number: GXMTB/RIF-US-10.Open, Classified
Z-0724-2026 · Started Nov 5, 2025 · Posted by FDA Nov 26, 2025
Reason given: Product testing did not meet expected stability criteria.
Cause as FDA categorized it: Under Investigation by firm · Device type: System, Nucleic Acid-Based, Mycobacterium Tuberculosis Complex, Resistance Marker, Direct Specimen (PEU)
Z-0959-2026 · Started Oct 30, 2025 · Posted by FDA Dec 18, 2025
Reason given: Invitro diagnostic test kits with specimens that have elevated white blood cell count (>30,000 cell) may cause inaccurate results.
Cause as FDA categorized it: Process design · Device type: Bcr/Abl1 Monitoring Test (OYX)
Z-0960-2026 · Started Oct 30, 2025 · Posted by FDA Dec 18, 2025
Reason given: Invitro diagnostic test kits with specimens that have elevated white blood cell count (>30,000 cell) may cause inaccurate results.
Cause as FDA categorized it: Process design · Device type: Bcr/Abl1 Monitoring Test (OYX)
16 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.